The Bacteriophage Market is attracting increasing investment as bacteriophages offer a highly targeted approach to bacterial control. The market reached USD 0.0548 billion in 2024 and is forecast to reach USD 0.0889 billion by 2035, growing at a CAGR of 4.5% over the forecast period.

The growing prevalence of antibiotic-resistant bacteria is one of the main factors supporting research into phage therapy. Unlike broad-spectrum antibiotics, bacteriophages can be selected to target particular bacterial strains, creating opportunities for more specialized treatment approaches. Increasing awareness of phage therapy is consequently encouraging pharmaceutical and biotechnology research.

The market extends beyond human therapeutics into food and agriculture. Bacteriophages are being investigated for applications involving food safety, bacterial contamination control, and agricultural biocontrol. This diversification gives industry participants opportunities to develop products for multiple end-use sectors rather than relying exclusively on pharmaceutical applications.

North America has established itself as the largest regional market, supported by research infrastructure and investment in biotechnology. Europe is also developing its phage research ecosystem, while Asia-Pacific presents substantial opportunities through increasing healthcare expenditure, biotechnology development, and research activity related to resistant bacterial infections.

Future growth is expected to be influenced by synthetic biology, engineered phages, improved delivery systems, and evolving regulatory frameworks. Greater collaboration between academic institutions, biotechnology companies, and healthcare organizations could help advance bacteriophage products from research programs toward broader commercial and clinical applications.